Satoru Iwase1, Takashi Kawaguchi2, Daisuke Yotsumoto3, Takako Doi4, Kyuichiro Miyara5, Hiroki Odagiri6, Kaoru Kitamura7, Keisuke Ariyoshi8,9, Tempei Miyaji10,11, Hiroto Ishiki1,10, Kenichi Inoue4, Chizuko Tsutsumi4, Yoshiaki Sagara3, Takuhiro Yamaguchi10,11,12. 1. Department of Palliative Medicine, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. 2. Department of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan. 3. Department of Breast Surgery, Sagara Hospital, 3-31 Matsubara-cho, Kagoshima City, Kagoshima, 892-0833, Japan. 4. Kamakura Breast Cancer Center, Shonan Memorial Hospital, 2-2-60 Fueda, Kamakura-shi, Kanagawa, 248-0027, Japan. 5. Miyara Clinic, 2-3-1 Iso, Urasoe, Okinawa, 901-2132, Japan. 6. Department of Breast Surgery, Hirosaki National Hospital, 1 Tomino-cho, Hirosaki, Aomori, 036-8545, Japan. 7. Nagumo Clinic Fukuoka, 2-8-1, Daimyo, Chuo-ku, Fukuoka, 810-0041, Japan. 8. Department of Palliative Medicine, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. k-ariyoshi@umin.ac.jp. 9. Japanese Organization for Research and Treatment of Cancer (JORTC), 1-5-9-206, Yanaka, Taito-ku, Tokyo, 110-0001, Japan. k-ariyoshi@umin.ac.jp. 10. Japanese Organization for Research and Treatment of Cancer (JORTC), 1-5-9-206, Yanaka, Taito-ku, Tokyo, 110-0001, Japan. 11. Department of Clinical Trial Data Management, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. 12. Division of Biostatistics, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Abstract
PURPOSE:Cancer-related fatigue (CRF) is one of the most common symptoms reported by cancer patients. This randomized trial investigated the efficacy of the amino acid jelly Inner Power(®) (IP), a semi-solid, orally administrable dietary supplement containing coenzyme Q10 and L-carnitine, in controlling CRF in breast cancer patients in Japan. METHODS:Breast cancer patients with CRF undergoing chemotherapy were randomly assigned to receive IP once daily or regular care for 21 days. The primary endpoint was the change in the worst level of fatigue during the past 24 h (Brief Fatigue Inventory [BFI] item 3 score) from day 1 (baseline) to day 22. Secondary endpoints were change in global fatigue score (GFS; the average of all BFI items), anxiety and depression assessed by the Hospital Anxiety and Depression Scale (HADS), quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC Breast Cancer-Specific QLQ (EORTC QLQ-BR23), and adverse events. RESULTS:Fifty-nine patients were enrolled in the study, of whom 57 were included in the efficacy analysis. Median patient age was 50 years. Changes in the worst level of fatigue, GFS, and current feeling of fatigue were significantly different between the intervention and control groups, whereas the change in the average feeling of fatigue was not significantly different between groups. HADS, EORTC QLQ-C30, andEORTC QLQ-BR23 scores were not significantly different between the two groups. No severe adverse events were observed. CONCLUSION: IP may control moderate-severe CRF in breast cancer patients. TRIAL REGISTRATION: The registration number of this study in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) is UMIN000008646.
RCT Entities:
PURPOSE:Cancer-related fatigue (CRF) is one of the most common symptoms reported by cancerpatients. This randomized trial investigated the efficacy of the amino acid jelly Inner Power(®) (IP), a semi-solid, orally administrable dietary supplement containing coenzyme Q10 and L-carnitine, in controlling CRF in breast cancerpatients in Japan. METHODS:Breast cancerpatients with CRF undergoing chemotherapy were randomly assigned to receive IP once daily or regular care for 21 days. The primary endpoint was the change in the worst level of fatigue during the past 24 h (Brief Fatigue Inventory [BFI] item 3 score) from day 1 (baseline) to day 22. Secondary endpoints were change in global fatigue score (GFS; the average of all BFI items), anxiety and depression assessed by the Hospital Anxiety and Depression Scale (HADS), quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC Breast Cancer-Specific QLQ (EORTC QLQ-BR23), and adverse events. RESULTS: Fifty-nine patients were enrolled in the study, of whom 57 were included in the efficacy analysis. Median patient age was 50 years. Changes in the worst level of fatigue, GFS, and current feeling of fatigue were significantly different between the intervention and control groups, whereas the change in the average feeling of fatigue was not significantly different between groups. HADS, EORTC QLQ-C30, and EORTC QLQ-BR23 scores were not significantly different between the two groups. No severe adverse events were observed. CONCLUSION: IP may control moderate-severe CRF in breast cancerpatients. TRIAL REGISTRATION: The registration number of this study in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) is UMIN000008646.
Entities:
Keywords:
Cancer-related fatigue; Chemotherapy-induced fatigue; Complementary and alternative medicine; Quality of life; Supplement
Authors: V Mock; A Atkinson; A Barsevick; D Cella; B Cimprich; C Cleeland; J Donnelly; M A Eisenberger; C Escalante; P Hinds; P B Jacobsen; P Kaldor; S J Knight; A Peterman; B F Piper; H Rugo; P Sabbatini; C Stahl Journal: Oncology (Williston Park) Date: 2000-11 Impact factor: 2.990
Authors: R C Kessler; R B Davis; D F Foster; M I Van Rompay; E E Walters; S A Wilkey; T J Kaptchuk; D M Eisenberg Journal: Ann Intern Med Date: 2001-08-21 Impact factor: 25.391
Authors: Julienne E Bower; Kate Bak; Ann Berger; William Breitbart; Carmelita P Escalante; Patricia A Ganz; Hester Hill Schnipper; Christina Lacchetti; Jennifer A Ligibel; Gary H Lyman; Mohammed S Ogaily; William F Pirl; Paul B Jacobsen Journal: J Clin Oncol Date: 2014-04-14 Impact factor: 44.544
Authors: D Tomlinson; P D Robinson; S Oberoi; D Cataudella; N Culos-Reed; H Davis; N Duong; F Gibson; M Götte; P Hinds; S L Nijhof; P van der Torre; S Cabral; L L Dupuis; L Sung Journal: Curr Oncol Date: 2018-04-30 Impact factor: 3.677
Authors: Tamara E Lacourt; Elisabeth G Vichaya; Gabriel S Chiu; Robert Dantzer; Cobi J Heijnen Journal: Front Behav Neurosci Date: 2018-04-26 Impact factor: 3.558